Drug development pipelines are increasingly incorporating synthetic control arms generated from real-world health data. The methodology reduces the number of physical patients required for control groups, significantly compressing trial initialization timelines.
Regulatory Acceptance Protocols
Regulatory agencies have begun issuing conditional guidance on the acceptable scope of synthetic data in rare disease studies. However, validation requirements remain stringent to ensure synthetic cohorts accurately replicate demographic and biomarker variance.